WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq: PPD) was named one of the �Best Workplaces in Greater China^� 2021� by Great Place to Work^� for successfully creating an inclusive workplace experience for employees.

PPD has more than 20 years of experience in the Asia-Pacific region, including providing a broad range of clinical development and laboratory services in Greater China. This is the second year PPD has received this recognition from Great Place to Work^�, a global authority on high-trust, high-performance workplace cultures.

�We remain committed to providing a healthy and open work environment for our employees, and this award shows that we continue to be successful in our efforts for yet another year,� said Ding Ming, Ph.D., vice president and general manager of PPD�s China operations. �PPD�s reputation in Greater China is a direct reflection of our inclusive culture, robust employee relations and attractive benefits. We continue to raise the bar as a preferred employer in this competitive market, and we remain dedicated to cultivating a diverse work atmosphere to attract and recruit highly qualified candidates to deliver quality results for our customers.�

Great Place to Work^� surveyed more than 150 companies in Mainland China, Hong Kong and Taiwan to assess employees' perceptions of leadership, organizational culture and trust. PPD was one of 61 companies named to the 2021 list.

PPD continues to expand in Asia-Pacific to serve local and global customers, with operations across the region. PPD provides a broad range of Phase I-IV services in Asia-Pacific, including clinical monitoring, project management, regulatory affairs, pharmacovigilance, data management and patient recruitment. Earlier this year, PPD opened its new multipurpose laboratory in Suzhou, China, to provide bioanalytical, biomarker and vaccine laboratory services to support Western and China-based pharmaceutical and biotech companies managing China research studies.

About PPD

PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our customers and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With more than 30,000 professionals worldwide, PPD has conducted clinical trials in more than 100 countries to help customers deliver life-changing therapies to improve health. We apply innovative technologies, therapeutic expertise and a firm commitment to quality to bend the cost and time curve of drug development and optimize value. For more information, visit www.ppd.com.

This news release contains forward-looking statements. These statements often include words such as �expect,� �believe,� �project,� �forecast,� �estimate,� �target� and other similar expressions. Although we believe these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our actual financial results, and therefore actual results might differ materially from those expressed in the forward-looking statements. Factors that might materially affect such forward-looking statements include, but are not limited to, the fragmented and highly competitive nature of the drug development services industry; changes in trends in the biopharmaceutical industry; our ability to keep pace with rapid technological changes that could make our services less competitive or obsolete; political, economic and/or regulatory influences and changes; the risks related to the proposed merger of PPD by Thermo Fisher Scientific Inc.; and other factors disclosed under the �Risk Factors� section in our periodic reports filed with the Securities and Exchange Commission (SEC), including our latest Annual Report on Form 10-K and Quarterly Report on form 10-Q, which are available on our website at https://investors.ppd.com or the SEC�s website at www.sec.gov. We assume no obligation and disclaim any duty to revise or update any forward-looking statements, or make any new forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.

Contacts

PPD Contacts
Media:

Nadine Maeser

+1 910 558 4779

[email protected]

Investors:

Tracy Krumme

+1 910 558 4186

[email protected]